Related Experiment Video
Updated: Aug 30, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
328
Hierarchical multi-class Alzheimer's disease diagnostic framework using imaging and clinical features
Yao Qin1, Jing Cui1, Xiaoyan Ge1
1Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China.
Frontiers in Aging Neuroscience
|August 29, 2022
Summary
This study developed a new framework combining brain imaging and cognitive tests for accurate Alzheimer's disease (AD) diagnosis. The approach achieved 87.7% accuracy in distinguishing normal cognition, mild cognitive impairment, and AD stages.
Area of Science:
- Neuroscience
- Medical Imaging
- Biostatistics
Background:
- Early diagnosis of Alzheimer's disease (AD) is challenging due to its clinical continuum.
- Current diagnostic accuracy for early stages of AD requires improvement.
Purpose of the Study:
- To create a hierarchical multi-class diagnostic framework for normal cognition (NC), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI), and AD.
- To investigate the geometric properties of cerebral cortical structures for diagnostic potential.
Main Methods:
- Utilized data from 1,670 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
- Extracted four cortical geometric properties (cortical thickness, fractal dimension, gyrification index, sulcus depth) for 148 anatomical structures.
- Integrated imaging features with Mini-Mental State Examination (MMSE) scores and applied AdaBoost algorithm with sparse learning for feature selection.
Main Results:
- Achieved an overall accuracy of 0.877 in the temporal validation set using the developed framework.
- Identified key discriminative imaging features, including cortical thickness and sulcus depth in specific brain regions like the posterior cingulate gyrus and superior temporal sulcus.
- Clinical Dementia Rating (CDR) emerged as a primary clinical variable associated with AD progression.
Conclusions:
- The hierarchical framework effectively combines cognitive variables and neuroimaging features for improved AD diagnosis.
- Surface-based morphometry and geometric analysis of cortical structures show reliability for early AD detection.
- This approach facilitates more accurate clinical diagnosis of Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Overview
650
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
650
Dementia
159
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
159
Alzheimer's Disease: Treatment
250
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
250

